New Post-Chemo Stem Cell Transplant Promising in MS

This article originally appeared here.
Share this content:
New Post-Chemo Stem Cell Transplant Promising in MS
New Post-Chemo Stem Cell Transplant Promising in MS

FRIDAY, June 10, 2016 (HealthDay News) -- A treatment combining chemotherapy and an autologous hematopoietic stem-cell transplantation (aHSCT) could represent a major advance against aggressive multiple sclerosis (MS), according to a study published online June 9 in The Lancet.

Harold Atkins, M.D., an associate professor of clinical hematology at the University of Ottawa in Canada, and colleagues treated 24 MS patients, aged 18 to 50. Autologous CD34 selected hematopoietic stem-cell grafts were collected following treatment with cyclophosphamide and filgrastim. Immunoablation was followed by aHSCT. Median follow-up was 6.7 years.

The researchers determined that the treatment stopped MS relapses and progression in 23 of 24 patients, and these 23 patients no longer needed medication to control their MS. Eight showed continued improvement for nearly eight years. Many of the patients had substantial recovery of neurological function. While improvement was notable, side effects were significant. One patient died from a liver infection, and eight had moderate toxic effects. Fourteen had mild side effects, the study authors said.

"We describe the first treatment to fully halt all detectable central nervous system inflammatory activity in patients with multiple sclerosis for a prolonged period in the absence of any ongoing disease-modifying drugs," the authors conclude. "Furthermore, many of the patients had substantial recovery of neurological function despite their disease's aggressive nature."

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

No Long-Term Health Issues for Infants With Isolated Oral Clefts

No Long-Term Health Issues for Infants With Isolated ...

However, cleft palate associated with increased risk for developmental problems

T2DM Predicts Mortality in Patients With Heart Failure

T2DM Predicts Mortality in Patients With Heart Failure

Type 2 diabetes mellitus predicts mortality, regardless of presence of ischemic heart disease

Unmet Needs for Non-HIV Care in Men Who Have Sex With Men

Unmet Needs for Non-HIV Care in Men Who ...

About 23 percent have unmet need for dental care, 19 percent have unmet need for eye or vision care

is free, fast, and customized just for you!

Already a member?

Sign In Now »